CD274 and non-small cell lung carcinoma: Similarly, in another Phase II study, sitravatinib (120 mg daily) combined with tislelizumab resulted in ORRs of 8.7% and 18.2% in patients with anti‐PD‐(L)1 resistant/refractory nonsquamous and squamous NSCLC (PFS, 4.2 and 5.3 months; OS, 10.1 and 10.5 months) [16], respectively.